Evidence map›Paper›PMID 35507486›Full record

ArticleThe New England journal of medicine2022

Baricitinib in Alopecia Areata.

Andrew Messenger, Matthew Harries

Registry-linked trialAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06065046 (A Randomized Control Trial of Baricitinib Administration in Patients With Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06065046 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

A Randomized Control Trial of Baricitinib Administration in Patients With Moderate and Severe Traumatic Intracerebral Hemorrhage/Contusions

TypeinterventionalSponsorTang-Du HospitalRan2023 to 2026Enrolled100ConditionsTraumatic Brain InjuryArmsBaricitinib 4 MG, Standard treatment
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Andrew MessengerFrom the Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield (A.M.), the Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford (M.H.), and the Centre for Dermatology Research, University of Manchester, Manchester Academic Health Science Centre and National Institute for Health Research Manchester Biomedical Research Centre, Manchester (M.H.) - all in the United Kingdom.
Matthew HarriesFrom the Department of Infection, Immunity, and Cardiovascular Disease, University of Sheffield, Sheffield (A.M.), the Dermatology Centre, Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford (M.H.), and the Centre for Dermatology Research, University of Manchester, Manchester Academic Health Science Centre and National Institute for Health Research Manchester Biomedical Research Centre, Manchester (M.H.) - all in the United Kingdom.
University of Manchester · GBUniversity of Sheffield · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alopecia AreataJanus Kinase InhibitorsAzetidinesHumansPurinesPyrazolesSulfonamidesAzetidinesbaricitinibJanus Kinase InhibitorsPurinesPyrazolesSulfonamides

Identifiers

PMID35507486
OpenAlexW4229042774

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.